Skip to content
    Life Sciences at Goldman Sachs Alternatives logo

    Life Sciences at Goldman Sachs Alternatives

    New York, New York, United StatesFounded 2021
    am.gs.com/en-us/advisors/products/life-sciences
    Biotech & Life SciencesHealthcare

    Life Sciences at Goldman Sachs Alternatives is the life sciences investing group within Goldman Sachs Asset Management, established in 2021 and led by Amit Kakar. It invests in privately-held, innovative therapeutics, life sciences tools, and diagnostics companies across areas such as precision medicine, genetic medicine, cell therapy, and immunotherapy, typically at early-to-mid and growth stages. Its debut fund, West Street Life Sciences I, closed at $650 million in early 2024.

    60% of their portfolio is in Biotech & Life Sciences. They made 3 investments in the last 12 months. Their most common stage is series-b (50% of deals). Average disclosed round size is $176.5M (across 10 rounds with reported amounts).

    Find people at Life Sciences at Goldman Sachs Alternatives on Goldilocks AI

    Portfolio

    8

    Fund Size

    $650M

    Top Stage

    Series B

    Last 12 Mo

    3

    Team

    CW

    Colin Walsh, PhD

    Managing Director, Life Sciences

    Portfolio Breakdown

    Stage Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    10 investments
    CompanyRoundAmountDate
    Vaderis Therapeutics logoVaderis TherapeuticsSeries B$152.5MAug 2026
    Sidewinder logoSidewinderSeries B$137MApr 2026
    Third Arc Bio logoThird Arc BioSeries A$52MFeb 2026
    SSidewinder TherapeuticsSeries B$137MJan 2026
    Sidewinder logoSidewinderSeries B$137MJan 2026
    AAirNexisSeries A$200MJan 2026
    MapLight Therapeutics logoMapLight TherapeuticsSeries D$372.5MJan 2025
    MapLight Therapeutics logoMapLight TherapeuticsSeries C$225MOct 2023
    Vaderis Therapeutics logoVaderis TherapeuticsSeries B$152MJan 2020
    AirNexis Therapeutics logoAirNexis TherapeuticsSeries A$200M—

    Top Co-Investors

    OrbiMed5 shared
    Frazier Life Sciences5 shared
    T. Rowe Price3 shared
    Omega Funds3 shared
    Longwood Fund3 shared
    Alexandria Venture Investments3 shared
    Novartis Venture Fund3 shared
    Samsara BioCapital3 shared
    Astellas Venture Management3 shared
    Goldman Sachs Alternatives2 shared
    Longitude Capital2 shared
    The Goldman Sachs Group, Inc.2 shared
    SR One2 shared
    Enavate Sciences2 shared
    EQT Life Sciences2 shared
    Medicxi2 shared
    Blue Owl Capital2 shared
    Sanofi Ventures2 shared
    Forbion2 shared
    Andreessen Horowitz (a16z) Bio + Health1 shared

    Last updated: 7 October 2026